BridgeBio Oncology Therapeutics, Inc. (BBOT) — Net Asset Quality Index
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Net Asset Quality Index of 89.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $417.65 Million minus total liabilities of $45.37 Million yields net assets of $372.28 Million. A higher index indicates a stronger, lower-leverage balance sheet. See BBOT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
BridgeBio Oncology Therapeutics, Inc. Net Asset Quality Index Over Time (2021–2025)
This chart shows how BridgeBio Oncology Therapeutics, Inc.'s Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the index stands at 89.1%, representing net assets of $372.28 Million against total assets of $417.65 Million USD. Explore BridgeBio Oncology Therapeutics, Inc. (BBOT) cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for BridgeBio Oncology Therapeutics, Inc. (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see BBOT stock market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 91.7% | $411.10 Million | $448.38 Million | $37.28 Million | ▼ -5.4 pp |
| 2024 | 97.1% | $188.72 Million | $194.42 Million | $5.71 Million | ▲ +116.2 pp |
| 2023 | -19.1% | $-63.57K | $332.89K | $396.46K | ▼ -4.0 pp |
| 2022 | -15.1% | $-21.88K | $144.58K | $166.46K | ▼ -2.4 pp |
| 2021 | -12.7% | $-18.36K | $144.28K | $162.64K | — |